Search research articles
Contact Us
Filters
Showing results (141-150 of 167) with videos related to
Page
of 17
Sort By:
Hepatology International
|
April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Journal of Hepatology
|
April 3, 2022
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
Maryam Barsch, Henrike Salié, Alexandra Emilia Schlaak, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 20, 2022
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia A M Fulgenzi, et al.
Liver Cancer
|
December 24, 2021
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
Petros Fessas, Muntaha Naeem, Matthias Pinter, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 28, 2022
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
Thomas Talbot, Antonio D'Alessio, Matthias Pinter, et al.
Hepatology (Baltimore, Md.)
|
March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
World Journal of Gastrointestinal Oncology
|
December 11, 2023
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Sirish Dharmapuri, Umut Özbek, Hiren Jethra, et al.
Hepatology Communications
|
October 27, 2023
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Vincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.
Cancers
|
December 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Yue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 167) with videos related to
Sort By:
Page
of 17
Hepatology International
|
April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Journal of Hepatology
|
April 3, 2022
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
Maryam Barsch, Henrike Salié, Alexandra Emilia Schlaak, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 20, 2022
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia A M Fulgenzi, et al.
Liver Cancer
|
December 24, 2021
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
Petros Fessas, Muntaha Naeem, Matthias Pinter, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 28, 2022
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
Thomas Talbot, Antonio D'Alessio, Matthias Pinter, et al.
Hepatology (Baltimore, Md.)
|
March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
World Journal of Gastrointestinal Oncology
|
December 11, 2023
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Sirish Dharmapuri, Umut Özbek, Hiren Jethra, et al.
Hepatology Communications
|
October 27, 2023
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Vincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.
Cancers
|
December 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Yue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.
Page
of 17